For immunochemical detection of MyD88
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

MyD88 (N-Term) Rabbit Monoclonal Antibody (Clone RM306)

Item No. 32250

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Synonyms
  • Myeloid Differentiation Primary Response Protein MyD88
Immunogen
Peptide from the N-terminal region of human MyD88
Clone Designation
RM306
Formulation (Request formulation change)
100 µl of protein A-affinity purified monoclonal antibody.
Storage Buffer
PBS with 50% glycerol, 1% BSA, and 0.09% sodium azide
Host
Rabbit
Isotype
IgG
Applications
IHC, WB
Cross Reactivity
(+) MyD88
Species Reactivity
(+) Human
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    100 µl

    $411

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    MyD88 is an adaptor protein involved in the innate immune response.1,2 It is composed of an N-terminal death domain, intermediate domain, and C-terminal toll-interleukin-1 receptor (TIR) domain.1 It is expressed in both myeloid and non-myeloid tissues, and its expression can be induced by immune-related factors, such as IL-6, LPS, and IFNs.2 As an adaptor protein, the TIR domain of MyD88 interacts with the TIR domain of toll-like receptor 1 (TLR1), -2, -4, -5, and -6, and IL-1 receptor (IL-1R) at the plasma membrane and TLR7, -8, and -9 at the endosomal membrane, while the MyD88 death domain interacts with IL-1R-associated kinases (IRAKs).1,3 In this way, MyD88 translates signals from TLRs and IL-1Rs to IRAKs, inducing signaling that leads to activation of NF-κB and subsequent cytokine production, as well as MAPK signaling.1,2 MyD88 is associated with inflammatory carcinogenesis but is also associated with protection from oncogenic pathogens.4 Mice deficient for Myd88 are protected from endotoxic shock induced by the TLR4 agonist LPS but have an increased susceptibility to bacterial pathogens and parasites.1 A leucine-to-proline mutation at position 265 of MYD88, within the TIR domain, is associated with certain cancers, including Waldenström’s macroglobulinemia and activated B cell diffuse large B cell lymphomas.5 Cayman’s MyD88 (N-Term) Rabbit Monoclonal Antibody (Clone RM306) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Deguine, J., and Barton, G.M. MyD88: A central player in innate immune signaling. F1000Prime Rep. 6, 97 (2014).

    2. Janssens, S., and Beyaert, R. A universal role for MyD88 in TLR/IL-1R-mediated signaling. Trends Biochem. Sci. 27(9), 474-482 (2002).

    3. Zheng, C., Chen, J., Chu, F., et al. Inflammatory tole of TLR-MyD88 signaling in multiple sclerosis. Front. Mol. Neurosci. 12, 314 (2020).

    4. Salcedo, R., Cataisson, C., Hasan, U., et al. MyD88 and its divergent toll in carcinogenesis. Trends Immunol. 34(8), 379-389 (2013).

    5. Yu, X., Li, W., Deng, Q., et al. MYD88 L265P Mutation in Lymphoid Malignancies. Cancer Res. 78(10), 2457-2462 (2018).